» Articles » PMID: 34326775

Progress in the Application of Drugs for the Treatment of Multiple Sclerosis

Overview
Journal Front Pharmacol
Date 2021 Jul 30
PMID 34326775
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple sclerosis (MS) is an autoimmune and chronic inflammatory demyelinating disease of the central nervous system (CNS), which gives rise to focal lesion in CNS and cause physical disorders. Although environmental factors and susceptibility genes are reported to play a role in the pathogenesis of MS, its etiology still remains unclear. At present, there is no complete cure, but there are drugs that decelerate the progression of MS. Traditional therapies are disease-modifying drugs that control disease severity. MS drugs that are currently marketed mainly aim at the immune system; however, increasing attention is being paid to the development of new treatment strategies targeting the CNS. Further, the number of neuroprotective drugs is presently undergoing clinical trials and may prove useful for the improvement of neuronal function and survival. In this review, we have summarized the recent application of drugs used in MS treatment, mainly introducing new drugs with immunomodulatory, neuroprotective, or regenerative properties and their possible treatment strategies for MS. Additionally, we have presented Food and Drug Administration-approved MS treatment drugs and their administration methods, mechanisms of action, safety, and effectiveness, thereby evaluating their treatment efficacy.

Citing Articles

Transcriptomic profiling identifies ferroptosis and NF-κB signaling involved in α-dimorphecolic acid regulation of microglial inflammation.

Zhu X, Wang P, Chao S, Tang W, Zhao L, Yu L J Transl Med. 2025; 23(1):260.

PMID: 40038710 PMC: 11877847. DOI: 10.1186/s12967-025-06296-7.


Exploring precision therapeutics: computational design of antisense oligonucleotides targeting AXL gene transcripts in multiple sclerosis treatment management.

Shreevatsa B, Nagaraj A, Dharmashekar C, Jain A, Harendra B, Siddalingegowda S Front Chem. 2025; 13:1548269.

PMID: 39974615 PMC: 11835993. DOI: 10.3389/fchem.2025.1548269.


Immunomodulatory effects of HYCO-3, a dual action CO-releaser/Nrf2 activator.

Stegnjaic G, Nikolovski N, Stanisavljevic S, Lazarevic M, Momcilovic M, Foresti R Clin Exp Immunol. 2024; 219(1).

PMID: 39540912 PMC: 11773809. DOI: 10.1093/cei/uxae100.


Immunoglobulin G and Complement as Major Players in the Neurodegeneration of Multiple Sclerosis.

Kennedy P, Fultz M, Phares J, Yu X Biomolecules. 2024; 14(10).

PMID: 39456143 PMC: 11506455. DOI: 10.3390/biom14101210.


A systematic review to explore patients' MS knowledge and MS risk knowledge.

Smith E, Langdon D Neurol Sci. 2024; 45(9):4185-4195.

PMID: 38700598 PMC: 11306520. DOI: 10.1007/s10072-024-07541-5.


References
1.
Wolinsky J, Narayana P, Nelson F, Datta S, OConnor P, Confavreux C . Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler. 2013; 19(10):1310-9. DOI: 10.1177/1352458513475723. View

2.
Buron M, Kalincik T, Sellebjerg F, Soelberg Sorensen P, Magyari M . Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study. J Neurol Neurosurg Psychiatry. 2021; 92(5):556-562. DOI: 10.1136/jnnp-2020-324869. View

3.
Imeri F, Stepanovska Tanturovska B, Zivkovic A, Enzmann G, Schwalm S, Pfeilschifter J . Novel compounds with dual S1P receptor agonist and histamine H receptor antagonist activities act protective in a mouse model of multiple sclerosis. Neuropharmacology. 2021; 186:108464. DOI: 10.1016/j.neuropharm.2021.108464. View

4.
Bigaut K, De Seze J, Collongues N . Ocrelizumab for the treatment of multiple sclerosis. Expert Rev Neurother. 2018; 19(2):97-108. DOI: 10.1080/14737175.2019.1561284. View

5.
Vergo S, Craner M, Etzensperger R, Attfield K, Friese M, Newcombe J . Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model. Brain. 2011; 134(Pt 2):571-84. DOI: 10.1093/brain/awq337. View